A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age
Latest Information Update: 05 Nov 2021
At a glance
- Drugs MEDI 3250 (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors MedImmune
- 30 Nov 2019 Results (n=200) published in the Vaccine
- 07 Oct 2018 Primary endpoint has been met. (Proportion of subjects with strain-specific hemagglutination inhibition seroconversion rates)
- 07 Oct 2018 Results presented at the IDWeek 2018